Lipicard 160 mg (Fenofibrate)

Product Overview

Lipicard 160 mg is a prescription medication that contains fenofibrate, a lipid‑lowering agent used to treat high cholesterol and elevated triglyceride levels. Manufactured by USV Pvt Ltd, each strip contains ten tablets of 160 mg fenofibrate. The product is indicated for patients with hypercholesterolemia or mixed dyslipidemia, especially when diet and exercise alone are insufficient. This SEO‑optimized description follows medical best practices and includes clinically relevant terms such as “high cholesterol,” “hyperlipidemia,” and “triglyceride management” to improve search visibility while maintaining medically responsible language.

What is Lipicard 160 mg?

Lipicard belongs to the class of fibrates, which act primarily on the peroxisome proliferator‑activated receptor‑alpha (PPAR‑α). Activation of PPAR‑α increases the expression of enzymes that break down fatty acids, leading to reduced triglyceride concentrations and modest increases in high‑density lipoprotein (HDL) cholesterol. The active ingredient fenofibrate is a prodrug that is hydrolyzed in the liver to the active form, which then modulates lipid metabolism. Lipicard 160 mg is marketed as a once‑daily tablet, providing a convenient option for long‑term lipid control.

Uses and Benefits

The primary use of Lipicard 160 mg is to lower elevated triglycerides and reduce low‑density lipoprotein (LDL) cholesterol in adults with hyperlipidemia. Clinical studies have demonstrated that fenofibrate therapy can decrease triglyceride levels by 30‑45 % and improve overall lipid profiles, thereby reducing the risk of atherosclerotic cardiovascular disease. Additional benefits include a modest rise in HDL‑C and a potential anti‑inflammatory effect on the vascular wall. When combined with a heart‑healthy diet, Lipicard can enhance the effectiveness of lifestyle interventions and support long‑term cardiovascular health.

How It Works

Fenofibrate exerts its pharmacological effect by activating PPAR‑α receptors in the liver, skeletal muscle, and adipose tissue. This activation up‑regulates genes involved in fatty‑acid oxidation and lipoprotein lipase activity, leading to increased clearance of triglycerides from the bloodstream. The drug also reduces hepatic synthesis of very‑low‑density lipoprotein (VLDL) particles, which are a major source of circulating triglycerides. By improving the lipid composition of plasma lipoproteins, fenofibrate helps to lower atherogenic cholesterol fractions and promote reverse cholesterol transport.

Dosage Guidelines

For most adults, the recommended starting dose of Lipicard 160 mg is one tablet taken orally once daily, preferably with a meal to enhance absorption and reduce gastrointestinal irritation. Patients with impaired renal function (creatinine clearance <30 mL/min) should avoid use or require dose adjustment, as fenofibrate is primarily eliminated renally. If a dose is missed, the patient should take it as soon as remembered unless it is near the time of the next scheduled dose; in that case, the missed dose should be skipped and the dosing schedule resumed. Chronic therapy typically continues as long as lipid targets are not achieved and tolerability remains acceptable.

Side Effects

Like all medications, Lipicard 160 mg may cause adverse effects. The most common side effects include abdominal pain, diarrhea, nausea, headache, and elevated liver enzymes. Less frequent but clinically important events comprise myopathy, rhabdomyolysis, and gallstone formation. Patients should be monitored for signs of liver dysfunction such as jaundice, dark urine, or persistent fatigue. If muscle pain, weakness, or unexplained bruising occurs, medical attention should be sought promptly, as these may indicate a rare but serious muscular toxicity.

Warnings and Precautions

Lipicard is contraindicated in patients with severe hepatic disease, active gallbladder disease, or known hypersensitivity to fenofibrate or any component of the formulation. It should not be used during pregnancy or breastfeeding unless the benefits outweigh the risks, and a healthcare professional should be consulted. Concomitant use with certain cholesterol‑lowering agents such as statins requires careful monitoring of liver enzymes and risk of myopathy. Patients with a history of pancreatitis, diabetes, or hypothyroidism should discuss potential interactions with their physician before initiating therapy.

Frequently Asked Questions

1. What is the difference between fenofibrate and other lipid‑lowering drugs? Fenofibrate belongs to the fibrate class and primarily targets triglycerides, whereas statins mainly lower LDL cholesterol. They can be prescribed together under medical supervision to achieve a more comprehensive lipid profile.
2. Can Lipicard be taken with food? Yes, taking Lipicard with a meal improves absorption and reduces the likelihood of gastrointestinal upset.
3. How long does it take to see a reduction in triglyceride levels? Clinical studies show measurable decreases in triglycerides within 2‑4 weeks of consistent daily dosing, with maximal effect often observed after 8‑12 weeks.
4. Is Lipicard safe for elderly patients? Elderly patients may have reduced renal function, so dose adjustment and regular monitoring of kidney function are recommended.
5. Where can I find more information about fenofibrate? Reliable sources include the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and MedlinePlus (MedlinePlus).

Related Products

• Glycomet 850 mg (Metformin)
• Glycomet GP 2 Tablet (Metformin/Glimepiride)
• Roseday 5 mg (Rosuvastatin)
• Erytop Gel (Clindamycin)
• Glycomet 250 mg (Metformin)
• Glycomet 500 mg (Metformin)
• Glycomet 1000 mg (Metformin)
• Glycomet GP 1 (Metformin/Glimepiride)
• Glycomet GP (Metformin/Glimepiride)
• Glynase XL (Glipizide)
• Glycomet GP 2 (Metformin/Glimepiride)
• Glynase XL 5 mg (Glipizide)